Study to Evaluate the Safety and Efficacy of a Low Level Light Device in Patients With Knee Osteoarthritis

August 12, 2009 updated by: Light Sciences LLC

A Phase I Single Center Open Label Study to Evaluate the Safety and Efficacy of a Low Level Light Device in Patients With Knee Osteoarthritis

This Phase I study is being conducted to examine the efficacy of the Light Sciences LLC (LSLLC) phototherapy device for home (self) treatment of knee osteoarthritis (OA).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This Phase I study is being conducted to examine the efficacy of the Light Sciences LLC (LSLLC) phototherapy device for home (self) - treatment of knee osteoarthritis (OA). Clinical efficacy will be assessed by evaluating the level of reported pain, including the use of analgesics, various measures of functional improvement, and clinical symptomology during a three week period of daily treatments. Durability of the clinical response for twelve weeks following therapy will also be examined. In addition, device safety will be assessed. As this is an early stage-prototype device, subject input regarding the usability of the device will be sought.

Subjects will be required to achieve three weeks of wash-out from all OA therapies prior to the start of phototherapy. Acetaminophen will be allowed during this time. During the three week active treatment and twelve week follow-up periods, subjects will be required to refrain from acetaminophen as well as OA therapies. However, subjects will be encouraged to speak with the investigator should any symptoms become difficult to manage. In addition to clinical assessments, subjects will be required to keep a daily diary.

The clinical objectives of the study will be met if at least five of ten subjects report decreased pain scores and improvement on an osteoarthritis index. While minimum or no safety issues are expected, the occurrence of skin changes to the area exposed to the device will be carefully monitored.

Study Type

Interventional

Enrollment (Anticipated)

10

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Washington
      • Kirkland, Washington, United States, 98034
        • Richard Neiman, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

36 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female
  • At least age 40 years
  • Community ambulator without orthoses
  • Knee circumference in range of 35.5 - 43 cm. (14-17 inches)
  • Moderate OA according to clinician judgment, and/or Radiographic evidence of knee OA of Kellgren-Lawrence Grade II or III in one or both knees.
  • Exercise induced pain, or for subjects who do not exercise, pain resulting from the activities of daily living, of at least 3 months duration
  • Knee pain of greater than 1 on VAS within the last 24 hours before evaluation.
  • Fitzpatrick type I, II, or III skin. (very light to darker Caucasian/light Asian.) (Selection avoids excessive light absorption in epidermis)
  • Understands and agrees to comply with all study procedures including the daily treatments and follow-up visits
  • Able to understand and is voluntarily willing to sign an informed consent form for this study

Exclusion Criteria:

  • Pregnant or nursing, or with the ability to become pregnant and not using an accepted form of birth control
  • Other causes of knee-related pain (e.g. hip OA, arterial insufficiency, etc) have been ruled out by physical examinations
  • Fitzpatrick type IV, V, or VI skin. (Mediterranean/Asian/Hispanic to dark-skinned black)
  • Any active Cancer
  • History of melanoma to the limb that is being evaluated in this study
  • Uncontrolled diabetes mellitus
  • Untreated hypertension
  • Skin conditions that would interfere with device use/placement
  • Psychotic disorder(s), dementia, mental retardation, or other organic mental disorders (subjects who are not mentally and physically able to personally consent for participation in this study are not eligible)
  • Any other (including acute) condition, which in the opinion of the investigator, is likely to cause non-compliance or significantly impact treatment outcomes.
  • Subject has received intra- or peri- articular steroid, or other, injection therapy within 6 months prior to enrollment in this study.
  • Enrolled in any other clinical trial within the last 6 weeks or enrollment in another clinical trial during participation in this trial.

Subjects who cannot be expected to be able to comply with the following restrictions during the course of their participation in the study, including during the washout period:

  • Prescription NSAID use prohibited
  • Use of photosensitizing drugs prohibited
  • Physiotherapy prohibited for treatment to the limb(s) that is being evaluated in this study.
  • Glucosamine use prohibited

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Decreased pain scores on the visual analog scale (VAS)
Improved Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) scores

Secondary Outcome Measures

Outcome Measure
Reduced use of over the counter (OTC) analgesics post therapy
Improved functionality as determined by measurable increases in knee range of motion (ROM)
Increased exercise ability
No, or decreased knee effusion
Subject satisfaction
Durability of the Clinical Response

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Light Sciences LLC

Investigators

  • Study Director: James C Chen, M.D., Light Sciences LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2006

Study Completion (Actual)

November 1, 2007

Study Registration Dates

First Submitted

September 11, 2006

First Submitted That Met QC Criteria

September 11, 2006

First Posted (Estimate)

September 13, 2006

Study Record Updates

Last Update Posted (Estimate)

August 14, 2009

Last Update Submitted That Met QC Criteria

August 12, 2009

Last Verified

August 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • C00011

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis, Knee

Clinical Trials on Low level light therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe